Skip to main content
. 2020 Jun 16;18:92. doi: 10.1186/s12951-020-00649-8

Fig. 3.

Fig. 3

In vitro drug release and therapeutic efficacy of 4T1 cells treated with different formulations. a Dox release from DPLGA NPs or DPLGA@[RAW-4T1] NPs at pH 4.7, 5.5, and 7.4. Cell viabilities of 4T1 cells incubated with Dox, DPLGA NPs, DPLGA@4T1 NPs, DPLGA@RAW NPs, and DPLGA@[RAW-4T1] NPs for 24 (b) and 48 h (c). d Analysis of apoptosis in 4T1 cells incubated with different groups for 48 h, followed by detection using the apoptosis kit of Annexin V-APC/PI by flow cytometry. e Invasion assay of cells treated with free Dox, DPLGA NPs, DPLGA@4T1 NPs, DPLGA@RAW NPs, and DPLGA@[RAW-4T1] NPs. Scale bar = 200 μm. f Scratch assay of cells treated with free Dox, DPLGA NPs, DPLGA@4T1 NPs, DPLGA@RAW NPs, and DPLGA@[RAW-4T1] NPs revealed wound closure. Scale bar = 200 μm. (mean ± SD, n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001